|Bid||232.01 x 800|
|Ask||233.62 x 800|
|Day's Range||227.66 - 232.95|
|52 Week Range||216.12 - 388.67|
|Beta (3Y Monthly)||1.62|
|PE Ratio (TTM)||10.02|
|Earnings Date||Jul 22, 2019 - Jul 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||258.79|
AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
MISSISSAUGA, ON, June 13, 2019 /CNW/ - Biogen Canada is pleased to announce that patients in Ontario living with spinal muscular atrophy (SMA) now have broader publicly funded access to SPINRAZA™ (nusinersen), the first and only treatment approved in Canada for SMA.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Data to be presented at the European Congress of Rheumatology (EULAR) 2019 highlight real-world evidence confirming the safety and efficacy of anti-TNF biosimilars and high.
Nasdaq: NITE), a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology.
In a webcast, the company outlined a strategy that focuses in the near term on rarer forms of amyotrophic lateral sclerosis, commonly known as Lou Gehrig’s disease.
Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)Growth driversSince the second quarter of 2016, Gilead Sciences (GILD) has been reporting major YoY (year-over-year) revenue declines, mainly due to its lower HCV
Roche's (RHHBY) performance has been strong in the year so far, driven by solid growth of Ocrevus, Perjeta, Tecentriq and Hemlibra.
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)MS revenue performance in the first quarterIn the first quarter, Biogen (BIIB) reported MS (multiple sclerosis) franchise revenue of ~$2.1 billion including
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)NASH failed trialsOn February 11, Gilead Sciences (GILD) issued a press release announcing the top line results from its Phase 3 STELLAR-4 study evaluating the
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)Failed programOn March 21, Biogen (BIIB) issued a press release announcing the discontinuation of its Phase 3 trials ENGAGE and EMERGE evaluating its leading
PDL BioPharma (PDLI) aims to acquire and manage high-yielding assets and maximize shareholder value. Blindly falling back on partners for royalties is a persistent concern.
Biogen Inc. (BIIB) announced today new interim data from the ongoing open-label, pivotal EVOLVE-MS-1 study indicate that the investigational treatment diroximel fumarate was generally well tolerated in people with relapsing multiple sclerosis (MS). Diroximel fumarate, a novel oral fumarate candidate in development with Alkermes plc (ALKS), is under review with the U.S. Food and Drug Administration with a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019.
Biogen stock has been through the wringer in 2019, and some think an acquisition could get it back on track. Here are several potential takeover targets.
Celgene's (CELG) Revlimid in combination with a rituximab product gets FDA approval for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.
ZURICH/NEW YORK, May 24, (Reuters) - Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million. The Food and Drug Administration approved Zolgensma for children under the age of two with SMA, including those not yet showing symptoms. "This is potentially a new standard of care for babies with the most serious form of SMA," said Dr. Emmanuelle Tiongson, a pediatric neurologist at Children's Hospital Los Angeles who has provided Zolgensma to patients under an expanded access program.
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.